Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial

SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis

(2021) Mahmoud Barbarawi et al.   HEART FAILURE REVIEWS

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

(2021) Stefan D. Anker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

(2020) Milton Packer et al.   CIRCULATION

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

(2020) Faiez Zannad et al.   LANCET

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

(2020) Darren K. McGuire et al.   JAMA Cardiology

Redefining Heart Failure With a Reduced Ejection Fraction

(2019) Javed Butler et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION